Table 3.
Cox regression analysis of risk factors for secondary generalization in patients with v-LOMG with pure ocular onset.
| Variables | HR | 95%CI | P-value |
|---|---|---|---|
| Gender, male vs. female | 0.691 | 0.243–1.962 | 0.487 |
| Onset age | 0.944 | 0.842–1.058 | 0.319 |
| Ptosis at onset, unilateral vs. bilateral | 1.086 | 0.235–5.016 | 0.916 |
| Diplopia at onset, yes vs. no | 1.045 | 0.362–3.017 | 0.935 |
| AChR antibody, positive vs. negative | 1.254 | 0.226–6.950 | 0.795 |
| RNS test, positive vs. negative | 2.188 | 0.756–6.332 | 0.149 |
| Thymic abnormalities, with vs. without | 0.778 | 0.223–2.723 | 0.695 |
| Concomitant diseases, with vs. without | 1.295 | 0.416–4.027 | 0.656 |
| Immunotherapy before generalization, with vs. without | 0.077 | 0.024–0.247 | <0.001 |
| Time from onset to immunotherapy initiation | 0.987 | 0.971–1.003 | 0.122 |
AChR, acetylcholine receptor; CI, confidential interval; v-LOMG, very-late-onset myasthenia gravis; HR, hazard ratio; RNS, repetitive nerve stimulation.